RXRX Tightens Cash, Advances AI Pipeline As Analysts Recalibrate

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

Recursion Pharmaceuticals (RXRX) stock rose 7.61% after positive AI-driven drug discovery results. The company reported Q2 2026 revenue of $7.7M, a net loss of $131M, and $545M in cash. It reduced its FY26 expense guidance to $375M, extending its cash runway into early 2028. Analysts have mixed views, with a consensus target of $7.22.

Analysts covering Recursion Pharmaceuticals (NASDAQ:RXRX) cut 2026 revenue forecasts by 19%, lowering consensus to about $53m, down 3.9% versus the prior 12 months. Loss per share is expected to improve slightly to about $0.88 versus $0.87 previously. The article also cites an expected annual revenue decline through 2026 versus prior growth.

Recursion Pharmaceuticals (Nasdaq: RXRX) reported second-quarter results for the period ended June 30, 2026 and provided pipeline updates. Genentech exercised an option to advance the collaboration’s first neuroscience target into an early discovery program. Recursion cut 2026 cash operating expense guidance to under $375 million. It also updated REC-4881 Phase 2 plans and said REC-7735 Phase 1/2 starts in 2H26.

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program • Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursi

Recursion said Genentech (Roche) exercised the first validated target option from a 4.5-year AI drug discovery collaboration. Acceptance triggers a $3 million milestone to Recursion, bringing total cash paid since 2021 to $216 million. Recursion can earn up to $300 million per program plus royalties. The target and indications are undisclosed.